预约演示

Fierce Pharma Asia—WuXi Bio's plunge; Daiichi-Novartis $182M settlement; Merck KGaA's Abbisko deal

2023-12-08

交易

并购临床3期细胞疗法专利侵权

WuXi Biologics' stock slide, Novartis and Daiichi Sankyo's settlement, and Merck KGaA and Abbisko's licensing deal made our news this week.

WuXi Biologics' gloomy busineNovartise triDaiichi Sankyo market avalanche. Merck KGaAnkyo Abbiskoartis reached a $182 million settlement on their BRAF drug patent dispute. Merck KGaA linked up with China's Abbisko Therapeutics on a phase 3 joint tumor med. And more.

WuXi Biologicsnufacturing giant WuXi Bio's stock plummets as it warns of $4Daiichi SankyossNovartis BRAF Merck KGaA Abbisko Therapeutics joint tumor

WuXi Biologics’ stock price plummeted about 24% Monday after the CDMO giant said it expects to miss this year’s revenue target by around $400 million. The company pointed to an industrywide downturn in COVID-related sales and challenges in biotech funding. The biologics manufacturer views the first half of 2024 as its darkest hours, with a positive turnaround in the second half of next year.

WuXi Biologicskyo scores $182M from Novartis settlement in long-running patent case

NovDaiichi Sankyoed to pay $182 millNovartisettle a patent dispute with Daiichi Sankyo. The case centers around Novartis’ melanoma drug Tafinlar. Daiichi’s former subsidiary Plexxikon, which developed rival BRAF drug Zelboraf, alleged that Tafinlar was made possible only because of discussions with Plexxikon about a partnership that never came to fruition.

Novartis KGaA buys into Abbisko’s late-stage joint tumor med for $70M upDaiichi Sankyo Novartis melanoma Tafinlar Daiichi Plexxikon BRAF Zelboraf Tafinlar Plexxikon

MerMerck KGaAid $70 millAbbiskoront to licensjoint tumorhina rights to Abbisko Therapeutics’ phase 3 candidate for tenosynovial giant cell tumor, a benign tumor of the joint. Development is underway to test the CSF-1R inhibitor, pimicotinib, in graft-versus-host disease and solid tumors. Merck has an option to expand the deal to other geographies.

Merck KGaAs expands radiotherapy manufacturing network with $85M plant Abbisko Therapeutics tenosynovial giant cell tumor benign tumor of the joint CSF-1R inhibitor CSF-1R pimicotinib graft-versus-host disease solid tumors Merck

NovNovartiss unveiled a plan to build a new radiotherapy manufacturing facility in China with an investment of about $85 million. The new plant, located in Haiyan about 60 miles from Shanghai, is expected to be operational for local production in 2026. The Chinese project adds to Novartis’ existing radiotherapy facilities in Italy, Spain and the U.S.

Novartisflying Fujifilm splashes $200M to beef up cell therapy capacityNovartis

Fujifilm plans Fujifilm $200 million between Fujifilm Cellular Dynamics and Fujifilm Diosynth Biotechnologies to expand its cell therapy capabilities. The former subsidiary, focused on human induced pluripotent stem cells, will get a new headquarters in Madison, Wisconsin; and the latter CDMO will expand an existing site in Thousand Oaks, California.

Fujifilm Africa's Aspen expands reach with $1Fujifilm Cellular Dynamicse busFujifilm Diosynth Biotechnologies

Sandoz is selling its China business to South Africa’s ASandozharmacare for about $100 million, with about $20 million tied to the future performance of Sandoz’s pipeline products. Aspen expects the deal to add about $96 million in annual sales, with such products such as the synthetic hormone injectable Sandostatin.

Sandozg Capital’s Concentra back with another buyout ofAspen Pharmacareor LianBioSandoz Sandostatin

LiaTang CapitalectConcentraolicited buyout proposal by Tang Capital PartneLianBiocentra Biosciences, saying the deal terms undervalue the company. LianBio, built on a business model of bringing innovative drugs to China and other Asian markets, recently launched a strategic review and sold certain Asian rights to mavacamten to Bristol Myers Squibb for $350 million.

LianBioews of Note:Tang Capital Partners Concentra Biosciences LianBio mavacamten Bristol Myers Squibb

8. FDA recommends avoiding plastic syringes made in China amid safety investigation

9. FDAh J&J settlement, Samsung Bioepis and Sandoz lock down Stelara biosimilar license

10. FDA J&Jts a flurry oSamsung Bioepisg recSandozy Teva, Glenmark, Apotex and VistaPharm

11. FDAa taps familiar friend Dr. Reddy’s to commercTevazeGlenmark Apotex VistaPharm